Find policies, billing codes, payers, states, and providers
Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage and reimbursement guidance for laboratory testing of parathyroid hormone (PTH), phosphorus, calcium, and magnesium for Oscar Health members, including indications, frequency limits for CKD and related disorders, and tests considered not meeting criteria.
No material clinical or coverage changes in this revision.
Coverage Criteria for PTH, Phosphorus, Calcium, and Magnesium Testing
Serum intact PTH — Medically necessary indications
Covered when ANY of the following are met:
from policy indications
see Note 1 in policy
policy lists osteoporosis/low bone mass
postoperative monitoring indication
policy frequency limits for CKD
per international consensus recommendations referenced in policy
policy stated annual testing for untreated hyperparathyroidism
policy lists MEN2A / familial MTC
Routine/wellness testing — Not medically necessary
Not covered for asymptomatic wellness visits or general exams without abnormal findings:
explicitly listed in policy
Guideline-aligned diagnostic and monitoring criteria
Coverage aligned with guideline-recommended testing when diagnostic or monitoring criteria are met:
AAES recommendation 1-1 and 1-2; see AAES chunks
AAES recommendations on postoperative assessment
First International Consensus and EuroPHPnet recommendations
International Workshop definition
CKD monitoring (KDIGO)
KDIGO — Monitoring of calcium, phosphate, and PTH by CKD stage
KDIGO recommendations and monitoring intervals
Kidney transplant monitoring (NKF KDOQI)
NKF KDOQI — Post-kidney transplant monitoring
NKF KDOQI transplant timing and supplementation guidance
PHPT diagnostic criteria (NICE)
NICE — Primary hyperparathyroidism (PHPT) diagnostic testing
NICE PHPT guideline statements
Hypoparathyroidism diagnosis and monitoring (ESE, ASBMR)
ESE / ASBMR — Hypoparathyroidism monitoring and diagnosis
ASBMR and ESE diagnostic criteria
ESE/ASBMR monitoring recommendations
Cancer-related laboratory monitoring (NCCN)
NCCN — Cancer-related testing where applicable
NCCN TLS and therapy-specific monitoring guidance
NCCN recommendation for bone cancer workup
Phosphate binder monitoring (NICE)
NICE — Phosphate binder therapy monitoring
NICE recommendations on binder selection and review
Guideline-derived monitoring recommendations
Guideline-based monitoring recommendations referenced in this section (examples by condition):
NICE guidance
ESE consensus
ASCO/CCO recommendation
AACE/ACE guidance
2025 multisociety consensus and ATA statements
AHA/ACC/HFSA guideline inclusion
ESE pregnancy monitoring guidance
Testing serum for truncated parathyroid hormone (PTH) metabolites (for example, amino‑terminal and carboxy‑terminal fragments) does not meet criteria. The policy states these assays are not supported because of a lack of published scientific literature demonstrating clinical benefit or necessity.
The policy discourages routine, blanket electrolyte testing in the emergency department for patients without documented risk factors. A retrospective ED study noted that clinical decision tools could identify patients at low risk for abnormal calcium and magnesium, and that testing only patients with risk factors would miss very few clinically significant abnormalities. Ordering electrolytes (Ca, Mg, PO4) without risk factors may therefore be considered over‑testing.
NICE guidance cited in the policy recommends that clinicians do not routinely measure calcium, phosphate, PTH, and vitamin D in people with an estimated GFR of ≥30 mL/min/1.73 m2 (GFR categories G1–G3). NICE instead recommends measuring these tests for patients in GFR categories G4 or G5 and determining subsequent testing frequency by measured values and clinical circumstances.
The policy references specialty guidance that advises against routine serum magnesium testing in certain populations. The SOGC (2014) guideline explicitly states that routine monitoring of serum magnesium in pregnancy is not recommended. Similarly, AGA guidance on chronic constipation indicates routine metabolic testing (including calcium) is not recommended in the absence of other clinical features; these sources support limited, indication‑based magnesium testing in pregnancy and pediatrics rather than universal screening.
This policy lists multiple evidence references and guideline sources (for example KDIGO, NKF KDOQI, NICE, ESE, AAES, AGA and NCCN) underpinning coverage and monitoring recommendations. The referenced sections provide the guideline context used to determine when testing is appropriate; the cited chunks do not, however, specify additional explicit exclusions beyond the not‑medically‑necessary items already listed in the policy.
Summary of tests considered not to meet criteria in this policy: serum truncated PTH metabolites (amino‑ and carboxy‑terminal fragments) are expressly listed as not meeting criteria, and routine metabolic testing during wellness or general exams — including serum magnesium, phosphorus, urine phosphorus, and serum or urine calcium — does not meet criteria when performed without abnormal findings.
Evidence cited suggests that indiscriminate electrolyte testing in the emergency department identifies very few additional clinically significant abnormalities: in one ED study, restricting calcium and magnesium testing to patients with clinical risk factors would have missed only about 1% of cases, supporting more selective testing in low‑risk presentations.
NICE guidance in the policy clarifies a GFR threshold for routine measurement: do not routinely test calcium, phosphate, PTH and vitamin D in people with eGFR ≥30 mL/min/1.73 m2 (G1–G3). Measurement is recommended for GFR categories G4 or G5, with subsequent testing frequency determined by results and clinical circumstances.
The policy cites guideline statements that routine metabolic testing is low yield in certain low‑risk clinical contexts. For example, the AGA (2013) recommends against routine metabolic testing (including serum calcium) for chronic constipation without other features, and SOGC guidance (2014) advises against routine serum magnesium monitoring in pregnancy—supporting an approach of testing only when clinical features warrant it.
Within the provided policy excerpts there are no additional explicit not‑medically‑necessary conditions named beyond those already listed (truncated PTH fragments and routine wellness/general exam metabolic testing). The referenced evidence and guideline lists support the policy recommendations but do not create further exclusions in these chunks.
Applicable Procedure Codes and Key Values
Provider Responsibilities, Prior Authorization, and Documentation
Authorization and medical necessity required
Services must meet authorization and medical necessity guidelines for the procedure, diagnosis, and the member's benefit coverage at the time of the request. Providers are responsible for accurate submission of documentation and appropriate coding; failure to follow coding/billing guidelines or reimbursement policies may result in claim denial or recoupment.
- Confirm member benefits and authorization requirements before ordering tests.
- Include clinical indication and relevant diagnostic data to support medical necessity on the claim.
No payer prior authorization specified
The policy text does not state any payer-specific prior authorization requirement for PTH, calcium, phosphate, or magnesium testing; clinical guidelines and the policy's coverage criteria should be used to justify testing when documentation is requested.
- No explicit payer prior authorization rule is listed in the document chunks cited.
Use guideline triggers to justify testing if requested
Although no explicit prior authorization rules are given, guideline-based triggers (for example CKD stage thresholds or NICE albumin-adjusted calcium thresholds) are the documented justification clinicians should cite if prior authorization or medical necessity documentation is requested.
- Use CKD/KDIGO stage-based monitoring intervals or NICE calcium thresholds as justification when supporting testing.
No explicit prior authorization requirement listed
The document contains no explicit requirement that prior authorization must be obtained for these tests; ordering clinicians should follow member benefit rules and applicable payer processes where present.
- If a conflict exists between this policy and government coverage (e.g., Medicare LCD/NCD), the government policy governs determinations.
Prior authorization not specified in these sections
Review of the provided policy chunks found no additional prior authorization requirements specified for PTH, phosphate, calcium, or magnesium testing in these sections.
- Proceed based on coverage criteria and member-specific benefit/contract rules.
Observe guideline monitoring cadence before escalation
Follow guideline-recommended monitoring cadence before escalating therapy: for pseudohypoparathyroidism and related disorders measure PTH, calcium, and phosphorus every 6 months in children and at least yearly in adults, with more frequent monitoring for symptomatic patients, during growth, pregnancy, or acute illness.
- Children: every 3–6 months (guideline examples cite every 3–6 months for some recommendations).
- Adults: at least yearly unless clinically indicated for more frequent monitoring.
Monitor calcium when using phosphate binders
When phosphate binders are prescribed for CKD patients, monitor serum phosphate and calcium at routine clinical reviews and reconsider calcium-based binder choice if serum calcium rises toward or above the age-adjusted upper normal limit.
- Assess phosphate control at each routine review and consider switching or reducing calcium-based binders if calcium rises.
No step therapy specified
No step therapy requirements are specified in the cited document chunks for PTH, calcium, phosphate, or magnesium testing or related treatments.
- Manage testing and treatment based on clinical guidelines and individualized patient needs.
Submit accurate documentation and standard coding
Providers must submit accurate clinical documentation and code according to industry-standard coding guidelines (CPT, HCPCS, ICD-10, etc.); failure to follow coding/billing guidance may result in denial or recoupment.
- Include clinical indication and supporting lab values/diagnoses on the claim.
- Use standard coding resources and follow CMS/CCI guidance where applicable.
Document required labs and timing for pHPT workup
For evaluation of suspected primary hyperparathyroidism, document serum total calcium, PTH, creatinine, and 25-hydroxyvitamin D; consider documenting timing of measurements and follow-up plans (for example, 6-month assessment of cure after parathyroidectomy).
- Include 24-hour urine calcium and creatinine when familial hypocalciuric hypercalcemia or hypercalciuria is a concern.
- Document timing of post-parathyroidectomy longitudinal testing (assess cure at 6 months).
Document CKD stage, GFR, and transplant timing for serial testing
When ordering serial calcium, phosphate, and PTH testing for CKD or transplant patients, document CKD stage, estimated GFR, baseline values, and time since transplant because recommended monitoring frequency differs by stage and time post-transplant.
- For transplant recipients, document time since transplant (e.g., first 3 months monitoring is more frequent: calcium/phosphate every 2 weeks; PTH monthly).
- Use KDIGO/NKF KDOQI monitoring tables to support frequency documented.
Document treatment modality and pregnancy/lactation status for HypoPT
For chronic hypoparathyroidism, document the treatment modality and pregnancy or lactation status because monitoring frequency recommendations differ (routine monitoring every ~3–6 months; pregnancy monitoring every 3–4 weeks and more frequently around delivery).
- Note therapy type (conventional therapy, recombinant PTH, supplements) and plan for urinary calcium monitoring if on conventional therapy.
Cite guideline and evidence references to support documentation
The policy includes numerous evidence references and guideline sources (KDIGO, NICE, AAES, ESE, NKF KDOQI, etc.) that can be cited to support medical necessity and clinical rationale in documentation, though no specific submission format is mandated.
- Reference the named guideline (e.g., KDIGO, NICE, AAES) appropriate to the clinical context in clinical notes when justifying testing frequency or indications.
Denial risk for improper coding or lack of medical necessity
Claims may be denied if coding/billing guidelines or reimbursement policies are not followed and if services do not meet authorization and medical necessity criteria; ensure documentation clearly links the test to a covered indication.
- Include specific covered indication from policy (for example: abnormal calcium, CKD stage with stated frequency, hypoparathyroidism evaluation).
Over-testing risk in emergency setting
Testing electrolytes (calcium, magnesium, phosphate) in the emergency department without documented risk factors may be considered over-testing; authors of a cited ER study found patients without risk factors were unlikely to have clinically significant abnormalities.
- Use documented risk factors or clinical decision tools to support ED electrolyte testing to reduce over-testing and potential denials.
Follow NICE albumin-adjusted calcium thresholds before PTH testing
Per NICE, measure PTH only when albumin-adjusted serum calcium meets the guideline thresholds: PTH is recommended if albumin-adjusted calcium is ≥2.6 mmol/L on at least two separate occasions, or ≥2.5 mmol/L on at least two occasions when features of PHPT are present; when measuring PTH a random sample concurrent with albumin-adjusted calcium is required.
- Repeat albumin-adjusted calcium in primary care if initial result is ≥2.6 mmol/L, or ≥2.5 mmol/L with features, before measuring PTH.
Follow applicable government coverage policies when they supersede
If there is a conflict between this policy and any applicable government policy (for example Medicare LCDs/NCDs or state Medicaid), the government policy will be used to make the determination; providers should verify and follow the most up-to-date government guidance when applicable.
- Check CMS LCD/NCD and state Medicaid rules for any member with Medicare/Medicaid coverage prior to ordering/testing.
No discrete denial triggers specified in these chunks
The cited document chunks do not list specific denial triggers beyond general statements; no discrete denial rules are specified in these sections.
- Use the policy's covered indications and guideline criteria to reduce risk of unsupported testing.
Clinical Background and Rationale
Parathyroid hormone (PTH), calcitriol and FGF23 are central regulators of calcium and phosphate homeostasis. PTH rapidly raises serum calcium through bone resorption and renal effects, while calcium circulates largely protein‑bound with approximately 45% ionized (active) fraction. PTH has a short half‑life and circulating truncated fragments can complicate measurement, which underlies the policy’s emphasis on using intact PTH assays and avoiding unsupported fragment assays.
Definitions and Measurement Considerations
Policy Revision History
Policy became effective on 2026-10-01.
Policy was last reviewed on 2026-06-16.
Publication action recorded on 06/16/2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.